基于ZUMA-7试验的日本二线axicabtagene ciloleucel与标准治疗的成本效用分析

数据集获取（Figshare）

• 源站标题：Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial
• DOI：10.6084/m9.figshare.27303863.v1
• 发布日期：2024-10-25
• 文件数：9 个
• 文件总体积：791.78 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost-utility_analysis_of_second-line_axicabtagene_ciloleucel_versus_standard_of_care_in_Japan_based_on_the_ZUMA-7_trial/27303863

命令行下载

curl -L -o "Fig. 2A.pdf" "https://ndownloader.figshare.com/files/49997279"
curl -L -o "Fig. 2B.pdf" "https://ndownloader.figshare.com/files/49997282"
curl -L -o "Fig. 2C.pdf" "https://ndownloader.figshare.com/files/49997288"
curl -L -o "Fig. 3.pdf" "https://ndownloader.figshare.com/files/49997291"
curl -L -o "Fig. 4A.pdf" "https://ndownloader.figshare.com/files/49997294"
curl -L -o "Fig. 4B.pdf" "https://ndownloader.figshare.com/files/49997297"
curl -L -o "Fig1.pdf" "https://ndownloader.figshare.com/files/49997300"
curl -L -o "Infographic_2L_ZUMA-7_CEA_Study_FINAL.pdf" "https://ndownloader.figshare.com/files/49997303"

文件清单

• Fig. 2A.pdf（48.67 KB）
• Fig. 2B.pdf（47.88 KB）
• Fig. 2C.pdf（49.08 KB）
• Fig. 3.pdf（39.94 KB）
• Fig. 4A.pdf（94.08 KB）
• Fig. 4B.pdf（48.92 KB）
• Fig1.pdf（129.10 KB）
• Infographic_2L_ZUMA-7_CEA_Study_FINAL.pdf（240.59 KB）
• Supplementary Material.docx（93.52 KB）

文件总体积 791.78 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Aim: To perform a cost–effectiveness analysis comparing axicabtagene ciloleucel (axi-cel) with standard of care (SoC; salvage chemoimmunotherapy, followed by high-dose therapy with autologous stem cell rescue for responders) for second-line (2L) treatment of adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) in the pivotal ZUMA-7 trial data from a Japanese payer perspective.
Materials & methods: A three-state partitioned survival model was utilized using population and clinical inputs from the ZUMA-7 trial data over a lifetime horizon.
Results: Axi-cel was associated with greater incremental quality-adjusted life-years (2.06) and higher incremental total costs ($48,685.59/¥6.9 million) leading to an incremental cost–effectiveness ratio of $23,590.34/¥3.3 million per quality-adjusted life-years compared with SoC.
Conclusion: Axi-cel is a cost-effective treatment alternative to SoC for 2L treatment of adults with r/r LBCL.
The current standard of care (SoC) for the treatment of relapsed or refractory large B-cell lymphoma (r/r LBCL) is associated with substantial economic burden due to associated poor outcomes and relatively longer hospital stays in the pre-CAR T era.
Current SoC therapies alone provide limited coverage to the rapidly aging Japanese population as advanced age precludes eligibility for transplant.
We conducted a cost–effectiveness analysis of second-line (2L) axicabtagene ciloleucel (axi-cel) versus current SoC for the treatment of adult patients with r/r LBCL from a Japanese payer perspective.
Our base case analysis showed that axi-cel treatment resulted in higher incremental effectiveness (2.06 quality-adjusted life-years [QALYs]) compared with SoC.
Substantial cost offsets (-$152,700.14/-¥1083 million)were observed with 2L axi-cel treatment for subsequent therapy and disease management leading to a modestly higher total cost ($50,252.99/¥6.9 million) and thus resulting in an incremental cost–effectiveness ratio (ICER) of $23,590.34 (¥3.3 million) per QALY gained, within the accepted willingness-to-pay (WTP) threshold ($53,191.49 [¥7.5 million] per QALY) from the Japanese payer perspective.
Therefore, treatment with axi-

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.27303863.v1（source: https://tandf.figshare.com/articles/dataset/Cost-utility_analysis_of_second-line_axicabtagene_ciloleucel_versus_standard_of_care_in_Japan_based_on_the_ZUMA-7_trial/27303863）。